Pharmaceutical contract manufacturing contributes significantly to the overall outsourcing market, due to its acceptance and widespread implementation by pharmaceutical companies. Cost reduction concerns originating from global economic constraints, has implied enormous pressure on pharmaceutical manufacturers to contain the cost of end-products. Pharmaceutical contract manufacturing divides production of goods by outside firms, under the brand of another firm, providing service to several manufacturers based on customized designs or specifications. Previously, pharmaceutical industry required companies to be vertically cohesive, i.e., the company itself conducted all operations required in production, however, currently investors require continued high fiscal performance, and as a result outsourcing has become a significant way of conducting business.
The global pharmaceutical market is going through critical change because of factors such as the need for reducing costs and minimizing product development rate, without conceding efficiency or production proficiency, decline in R&D activity, reduction in patent tenure, and growing innovative drugs are demanding pharmaceutical and bio-technology companies to drag drug prices. However, due to the economic slow-down in European countries, major pharma and biotechnology companies are ready to drop down their spending, resulting in increased contract manufacturers, globally.
Merger and acquisition activity has been widespread among both benefactor companies and contract manufacturers, leading to amalgamation among both sectors. Several pharmaceutical companies have acquired contract manufacturers to attain vertical integration. Other companies have adopted investment in their own manufacturing capabilities by developing concise, adaptable, multi-product facilities designated to meet the changing needs of pharmaceutical market. Both strategies are appointed to restrict the demand for outsourcing. Hence, contract service providers that demand growth going forward are expected to provide added-value to finished products for attracting pharmaceutical contractors. Emerging economies, super generics, and bio-similar products provide other latent prospects for growth with contract manufacturers attaining global reach and technical capabilities required to exploit them.
The global pharmaceutical contract manufacturing market is segmented by type of contract manufacturing and regions. By type of contract manufacturing, the pharmaceutical contract manufacturing market is segmented into advanced drug delivery products, final dosage form (FDF), active pharmaceutical ingredients (API)/bulk drug, packaging contract manufacturing and OTC medicines and nutritional products. The final dosage form (FDF) of contract manufacturing is estimated to develop with substantial rate due to increasing need for generic drug products and rising R&D activities. Geographically, world pharmaceutical contract manufacturing market is divided into North America, Europe, Asia-Pacific and Latin America and Middle East and Africa. The demand in Asia-Pacific is analyzed to be the major driving factor for the growth of the global pharmaceutical contract manufacturing market. China is analyzed to lead the demand for pharmaceutical contract manufacturing due to increased industrial production in the last 3–4 years. It is the leading consumer of pharmaceutical contract manufacturing in the world. The markets in other emerging economies such as Brazil and India are also projected to grow rapidly.
Key players involved in the global pharmaceutical contract manufacturing market are focusing on key market strategies including mergers and acquisitions with local as well as established players. Moreover, companies are also focusing on collaborating with local players to increase their reach across all geographies and earn huge profits. Partnership with multinational companies to strengthen their market reach and goodwill is also anticipated to be a major market strategy in the global pharmaceutical contract manufacturing market. Some of the major players involved in the manufacture and supply of pharmaceutical contract manufacturing include Aenova, Fareva, Catalent, Lonza, Amgen, Gedeon Richter, Apotex, AstraZeneca, Baxter, Cipla, Biocon Boehringer Ingelheim, Pfizer CentreOne, Celltrion, Coherus Biosciences, Berlin-Chemie, Daiichi Sankyo, Abbott, Dr. Reddy's Laboratories, , Biogen, Eli Lilly, Emcure Pharmaceuticals, Aspen, Eurofarma Laboratories, Gilead Sciences, Aurobindo Pharma, and GlaxoSmithKline (GSK).
Market by Type
· Advanced drug delivery products
· Final dosage form (FDF)
· Active pharmaceutical ingredients (API)/bulk drug
· Packaging contract manufacturing
· OTC medicines and nutritional products
Market by Geography
· North America
o Rest of Europe
o Rest of Asia-Pacific
· Latin America
o Rest of Latin America
· Middle East and Africa (MEA)
o South Africa
o Saudi Arabia
o Rest of MEA
Introduction The global breastfeeding accessories Market is projected worth US$ 1,470.6 million by 2026 and the market is projected to showcase 10.5% CAGR during the forecast period. The breastfeeding accessories market is driven by a rise in population of working mother, the rise in birth rate and fast-paced lifestyle.
Introduction ECG Equipment and Management Systems is a gadget which records the heart exercises through electric signals and are enhanced on the ECG screen. ECG Equipment and Management Systems are utilized to analyze sorts of heart illnesses and arrhythmias in an individual's body in this manner help the suitable treatment. The ECG test is noninvasive and effortless method and decides irregularity designs
Introduction Ear, nose and throat are some of the most vital parts of the human body. It is very important to keep the functions of these parts properly. There are many factors that affect the normal functioning of these organs such as sinusitis and aging. ENT, a prominent amongst the most vital parts of medical science is basically focusing on diagnosis and treatment of the different issues related with e
Introduction The global macular degeneration treatment Market is estimated to value US$ 11.4 Billion by 2026 and the market is projected to showcase 6.6% CAGR during the forecast period. The macular degeneration treatment market is driven by surge in healthcare spending and improved in healthcare infrastructure. Market D
Introduction The world-wide Anticoagulants market is expected to garner USD 39 billion by 2026 and the market is expected to register CAGR growth over 7.9% during the next eight years. Market Dynamics Growing need for controlling the diseases such as kidney diseases and cardi
Introduction The global Gynecological Devices market was valued at $9.4 billion in 2018 and is anticipated to grow at a CAGR of 7.9% during the forecast period. Gynecological devices include instruments and devices used for the treatment of diseases related to the female reproductive system. These devices include surgical devices, handheld instruments, diagnostic i